A public listing would also give an exit route to existing financial investors including TPG Capital, the people said. The sole contender for the stake, Bain Capital, also has been re-evaluating its plan, especially due to the $800 million to $1 billion (₹6,500-8,300 crore) valuation that the promoters, the Kanumuri family, have been expecting for the pharmaceutical contract research, development and manufacturing organisation, they said.
Nifty Outlook: Analysts pick key levels and stocks to watch
Nifty has experienced a decline for four straight weeks, breaking through the crucial 24,000 support level. Experts recommend adopting a market-neutral approach to capitalize on
September 7, 2026